PHASE II STUDY TO ASSESS THE TOLERABILITY, SAFETY AND EFFICACY OF SUBLINGUAL IMMUNOTHERAPY IN PATIENTS SUFFERING FROM GRASS POLLEN ALLERGY
Latest Information Update: 23 Nov 2020
At a glance
- Drugs Allergy immunotherapy (Primary)
- Indications Allergic rhinitis; Allergic rhinoconjunctivitis
- Focus Therapeutic Use
- Acronyms SULGEN Phleum pratense Study
- Sponsors Roxall Medizin GmbH
- 23 Nov 2020 New trial record